Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments

dc.contributor.authorCéline Blant, Julie
dc.contributor.authorDe Rossi, Nicola
dc.contributor.authorGold, Ralf
dc.contributor.authorMaurousset, Aude
dc.contributor.authorKraemer, Markus
dc.contributor.authorRomero Pinel, Lucía María
dc.contributor.authorMisu, Tatsuro
dc.contributor.authorOuallet, Jean Christophe
dc.contributor.authorPallix Guyot, Maud
dc.contributor.authorGerevini, Simonetta
dc.contributor.authorBakirtzis, Christos
dc.contributor.authorPiñar Morales, Raquel
dc.contributor.authorVlad, Benjamin
dc.contributor.authorKarypidis, Panajotis
dc.contributor.authorMoisset, Xavier
dc.contributor.authorDerfuss, Tobias J.
dc.contributor.authorJelcic, Ilijas
dc.contributor.authorMartin Blondel, Guillaume
dc.contributor.authorAyzenberg, Ilya
dc.contributor.authorMcgraw, Corey
dc.contributor.authorAxel Laplaud, David
dc.contributor.authorLebrun Frenay, Christine
dc.contributor.authorDu Pasquier, Renaud A.
dc.contributor.authorBernard Valnet, Raphael
dc.contributor.authorThe Corpus And Italian Pml Study Groups, For
dc.date.accessioned2026-06-15T09:42:38Z
dc.date.available2026-06-15T09:42:38Z
dc.date.issued2026-02-20
dc.date.updated2026-05-14T11:35:28Z
dc.description.abstractBackground and Objectives JC virus (JCV) reactivation causing progressive multifocal leukoencephalopathy (PML) is a complication in patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs). Although natalizumab (NTZ) is most frequently involved, PML also occurs less commonly with sphingosine-1-phosphate receptor modulators (S1P-RM), dimethyl fumarate (DMF), and ocrelizumab. This study aimed to identify factors predicting worse outcomes, focusing on the influence of PML-immune reconstitution inflammatory syndrome (PML-IRIS), plasma exchange (PlEx), corticosteroids, and DMT reintroduction. Methods This retrospective multicenter cohort study analyzed patients with MS who had JCV-associated pathology (PML or granule cell neuronopathy) from 42 centers (2009-2022). The primary outcome was disability at 12 months, measured by the modified Rankin Scale (mRS). Multivariable analyses identified predictors of poor outcomes, PML-IRIS development, and recurrent MS activity. Results Of 96 identified patients, 94 were analyzed. Most cases occurred under NTZ (77%), followed by S1P-RM (22%) and DMF (1%). Twelve-month survival was 91.5%, with a median mRS of 3 [IQR: 2-4]. Multivariable analysis showed that higher pre-PML disability (OR: 1.95 [95% CI 1.46-2.60], p < 0.001), elevated CSF JCV viral load (OR: 2.45 [95% CI 1.55-3.87], p < 0.001), and symptomatic presentation at onset (OR: 3.93 [95% CI 1.23-12.55], p = 0.021) were associated with worse outcomes. Conversely, PML-IRIS was associated with better outcomes (OR: 0.28 [95% CI 0.09-0.86], p = 0.025). PlEx and corticosteroid use had no negative effect. Discussion This study provides valuable insights into the management of iatrogenic PML in patients with MS. The findings may guide clinicians in making informed decisions, particularly regarding the use of PlEx, corticosteroids, and the management of PML-IRIS.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2332-7812
dc.identifier.pmid41719500
dc.identifier.urihttps://hdl.handle.net/2445/230039
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1212/NXI.0000000000200558
dc.relation.ispartofNeurology Neuroimmunology & Neuroinflammation, 2026, vol. 13, issue. 3, p. e200558
dc.relation.urihttps://doi.org/10.1212/NXI.0000000000200558
dc.rightscc-by (c) Céline Blant, Julie et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationAvaluació de resultats (Assistència mèdica)ca
dc.subject.classificationEsclerosi múltipleca
dc.subject.classificationMalalties cròniquesca
dc.subject.otherOutcome assessment (Medical care)en
dc.subject.otherMultiple sclerosisen
dc.subject.otherChronic diseasesen
dc.titleOutcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
blant-et-al-2026-outcome-predictors-in-progressive-multifocal-leukoencephalopathy-associated-with-multiple-sclerosis.pdf
Mida:
832.69 KB
Format:
Adobe Portable Document Format